EP0866716A4 - Verfahren zur behandlung von störungen des nichtvisuellen sensorischen epithels - Google Patents

Verfahren zur behandlung von störungen des nichtvisuellen sensorischen epithels

Info

Publication number
EP0866716A4
EP0866716A4 EP96940360A EP96940360A EP0866716A4 EP 0866716 A4 EP0866716 A4 EP 0866716A4 EP 96940360 A EP96940360 A EP 96940360A EP 96940360 A EP96940360 A EP 96940360A EP 0866716 A4 EP0866716 A4 EP 0866716A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating disorders
visual sensory
sensory epithelia
epithelia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96940360A
Other languages
English (en)
French (fr)
Other versions
EP0866716A1 (de
Inventor
Mark A Marchionni
Nagesh K Mahanthappa
Gerald Schwarting
Jeffrey Corwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ek Shriver Center Formental Retardation
UVA Licensing and Ventures Group
Cenes Pharmaceuticals Inc
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Cambridge Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation, Cambridge Neuroscience Inc filed Critical University of Virginia UVA
Publication of EP0866716A1 publication Critical patent/EP0866716A1/de
Publication of EP0866716A4 publication Critical patent/EP0866716A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP96940360A 1995-11-13 1996-11-12 Verfahren zur behandlung von störungen des nichtvisuellen sensorischen epithels Withdrawn EP0866716A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US654195P 1995-11-13 1995-11-13
US6541P 1995-11-13
PCT/US1996/018031 WO1997017983A1 (en) 1995-11-13 1996-11-12 Methods of treating disorders of non-visual sensory epithelia

Publications (2)

Publication Number Publication Date
EP0866716A1 EP0866716A1 (de) 1998-09-30
EP0866716A4 true EP0866716A4 (de) 2002-05-02

Family

ID=21721382

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96940360A Withdrawn EP0866716A4 (de) 1995-11-13 1996-11-12 Verfahren zur behandlung von störungen des nichtvisuellen sensorischen epithels

Country Status (4)

Country Link
EP (1) EP0866716A4 (de)
JP (1) JP2000505781A (de)
AU (1) AU727037B2 (de)
WO (1) WO1997017983A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
DE19807426A1 (de) 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US7132406B2 (en) 1998-02-23 2006-11-07 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
US6080845A (en) * 1998-08-05 2000-06-27 Amgen Inc. Monoclonal antibody against utricular epithelium
US6838444B1 (en) 1999-06-01 2005-01-04 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015812A1 (en) * 1994-11-17 1996-05-30 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015812A1 (en) * 1994-11-17 1996-05-30 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIRCHMEIER-C ET AL.: "Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells", INTERNATIONAL REVIEW OF CYTOLOGY, vol. 160, 1995, pages 221 - 266, XP001053100 *
CARRAWAY KL. ET AL.: "Neuregulins and their receptors", CURRENT OPINION IN NEUROBIOLOGY, vol. 5, October 1995 (1995-10-01), pages 606 - 612, XP001052960 *
MARCHIONNI-MA ET AL.: "Glial growth factros are alternatively spliced erbB2 ligands expressed in the nervous system", NATURE, vol. 362, 25 March 1993 (1993-03-25), pages 312 - 318, XP002188342 *
See also references of WO9717983A1 *

Also Published As

Publication number Publication date
AU727037B2 (en) 2000-11-30
WO1997017983A1 (en) 1997-05-22
AU7725896A (en) 1997-06-05
EP0866716A1 (de) 1998-09-30
JP2000505781A (ja) 2000-05-16

Similar Documents

Publication Publication Date Title
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
AU4918796A (en) Methods of treating or preventing psychiatric disorders
ZA965088B (en) Methods of preventing or treating allergles
GB2298440B (en) Well treatment
EP0820467A4 (de) Verfahren zur behandlung von augenkrankheiten
EP0651650A4 (de) METHODE ZUR BEHANDLUNG VON AUGENKRANKHEITEN MITTELS TGF--g(b).
EP0729361A4 (de) Verfahren zur behandlung neurologischer erkrankungen
PL350961A1 (en) Method of treating neurological and neuropsychiatric disorders
EP0819008A4 (de) Verfahren zur verwendung von lektinen zur prävention und behandlung von hautkrankheiten und hautunregelmässigkeiten
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
PL332313A1 (en) Application of benzopyranoles in treatment of neurological disorders
EP0866716A4 (de) Verfahren zur behandlung von störungen des nichtvisuellen sensorischen epithels
ZA969320B (en) Treatment of traumatic brain injury
PL322625A1 (en) Benzamides for treating neurodegenerative disorders
IL124786A0 (en) Method for treating pain
GB9419048D0 (en) Treatment of muscular disorders
EP0828507A4 (de) Verfahren zur behandlung von schmerz
EP0732938A4 (de) Verfahren zur behandlung von intestinalen störungen
GB9507825D0 (en) Method of treatment
GB9513034D0 (en) Treatment of neurological and psychiatric disorders
GB9613362D0 (en) Treatment of neurological and psychiatric disorders
GB9407335D0 (en) Method of treatment
GB9413556D0 (en) The treatment of neurological and psychiatric disorders
GB9324568D0 (en) Treatment of neurological and psychiatric disorders
GB9223953D0 (en) Treatment of eye disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020315

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: E.K. SHRIVER CENTER FORMENTAL RETARDATION

Owner name: THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Owner name: CENES PHARMACEUTICALS, INC.

17Q First examination report despatched

Effective date: 20030121

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: E.K. SHRIVER CENTER FORMENTAL RETARDATION

Owner name: THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Owner name: CENES PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050601